Testing a blood marker to predict worsening lung mycobacterial disease
Part of Infections, Lungs & breathing clinical trials.
This study checks whether a blood test called soluble programmed death-1 can help predict how nodular-bronchiectatic nontuberculous mycobacterial (NTM) lung disease will progress. Results may help doctors monitor patients more accurately and decide when to treat or follow more closely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 20 or older
- Have lung symptoms and chest imaging, and meet the study’s lung mycobacteria (NTM) diagnosis criteria (or be in one of the specific comparison groups described below)
- Be willing to provide sample(s) related to lung testing (such as sputum/culture results) and a blood test for the study marker
- If you have pulmonary tuberculosis (TB), you must have culture-positive TB or typical TB lung findings to join the TB group
- If you are a “healthy control,” you must be without the lung disease being studied
- Do not have acquired immunodeficiency syndrome (AIDS)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your diet (nutrition) and your immune system's T cells (a type of white blood cell) may affect the progression of a lung infection caused by nontuberculous mycobacteria (NTM). Researchers will use samples from a bronchoscopy to check your immune activity and nutrition, which may help understand the disease and guide better care.
This study looks at the characteristics of nontuberculous mycobacterial (NTM) lung disease and how the bacteria avoid the body's immune system. It helps doctors understand this condition better and improve future treatments.
This study follows people with a newly diagnosed MAC lung infection (a specific type of mycobacterial disease) and tests how they do on the standard three-drug treatment plan. It may help researchers better understand outcomes and safety for this condition.
This study compares the health of people with NTM lung disease (not on antibiotics) to people with bronchiectasis (who have never had NTM infection). It aims to understand how these conditions affect daily life.
This study looks at the community of tiny organisms in the lungs (the lung microbiome) in people with bronchiectasis caused by NTM (non-tuberculous mycobacteria). It compares people with positive NTM cultures to people without, to better understand what’s going on in the lungs and why symptoms may differ.
This trial studies whether a program of exercise and airway clearance education helps people with nontuberculous mycobacterial (NTM) lung disease. It aims to improve breathing and quality of life.
Hear when a new Nontuberculous Mycobacterial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.